Computational Antivirals forSudan ebolavirus
Design antiviral peptides, de novo binders, and validated leads. Use state of the art AI and structure based methods, no wet lab required to get to a ranked candidate list.
- Peer-Reviewed Publication
- 1Peer-Reviewed Publication
- Lead Candidates Identified
- 5Lead Candidates Identified
- Scientific Collaboration Initiated
- 1Scientific Collaboration Initiated
Supported by
Platform
One workflow, from viral target to validated candidate
Representative peptide fold · PDB 2MLT
Design antiviral peptides at computational scale and speed
- De novo binder design against a defined epitope
- Sequence ranking by predicted binding affinity
- Iterative refinement of top-scoring candidates
- Developability and stability screening
Computational first
A central workflow built on published methods
We connect established structural biology and machine learning methods into one discovery workflow, rather than rebuilding the field from scratch. The result is a search that narrows fast and stays explainable.
Built for scale
Search a space no laboratory could screen by hand
Computational screening lets us evaluate vastly more candidates than bench work alone would allow, and discard the ones that fail before they consume reagents, time or funding.
Designed for validation
Nothing stays theoretical
A computational result is a hypothesis. Our workflow is built so that every prioritised candidate has a defined route into experimental testing with partner laboratories.
Rigour & ownership
Peer-reviewed science, African-owned
How we work with partners on evidence, intellectual property and data.
Peer-reviewed foundations
Our lead program rests on published, peer-reviewed work. Every claim we make about the discovery workflow traces back to science that has been through review.
African-led ownership
Mara Biosciences is an African venture and intends its intellectual property to stay that way, with partnership structures that keep discovery capacity on the continent.
Clear data terms
Collaborators know upfront how sequence data, assay results and candidate structures are handled, shared and published across a partnership.
Contact
Let's Build the Next Generation of Antivirals
Whether you are a researcher, funding organisation, biotechnology company or global health partner, we would love to explore collaboration.